BRCA1, BRCA2 and PALB2 mRNA Expression as Prognostic Markers in Patients with Early Breast Cancer

被引:1
|
作者
Shehaj, Ina [1 ]
Krajnak, Slavomir [1 ]
Almstedt, Katrin [1 ]
Degirmenci, Yaman [1 ]
Herzog, Sophia [1 ]
Lebrecht, Antje [1 ]
Linz, Valerie Catherine [1 ]
Schwab, Roxana [1 ]
Stewen, Kathrin [1 ]
Brenner, Walburgis [1 ]
Hasenburg, Annette [1 ]
Schmidt, Marcus [1 ]
Heimes, Anne-Sophie [1 ]
机构
[1] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Obstet & Gynecol, D-55131 Mainz, Germany
关键词
mRNA expression; BRCA1; BRCA2; PALB2; metagene; breast cancer; HETEROGENEITY; PROTEIN; IMPACT;
D O I
10.3390/biomedicines12061361
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Breast cancer (BC) poses a challenge in establishing new treatment strategies and identifying new prognostic and predictive markers due to the extensive genetic heterogeneity of BC. Very few studies have investigated the impact of mRNA expression of these genes on the survival of BC patients. Methods: We examined the impact of the mRNA expression of breast cancer gene type 1 (BRCA1), breast cancer gene type 2 (BRCA2), and partner and localizer of BRCA2 (PALB2) on the metastasis-free survival (MFS) of patients with early BC using microarray gene expression analysis. Results: The study was performed in a cohort of 461 patients with a median age of 62 years at initial diagnosis. The median follow-up time was 147 months. We could show that the lower expression of BRCA1 and BRCA2 is significantly associated with longer MFS (p < 0.050). On the contrary, the lower expression of PALB2 was correlated with a shorter MFS (p = 0.049). Subgroup survival analysis identified the prognostic influence of mRNA expression for BRCA1 among patients with luminal-B-like BC and for BRCA2 and PALB2 in the subset of patients with luminal-A-like BC (p < 0.050). Conclusions: According to our observations, BRCA1, BRCA2, and PALB2 expression might become valuable biomarkers of disease progression.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
    Max M. Wattenberg
    Daniella Asch
    Shun Yu
    Peter J. O’Dwyer
    Susan M. Domchek
    Katherine L. Nathanson
    Mark A. Rosen
    Gregory L. Beatty
    Evan S. Siegelman
    Kim A. Reiss
    British Journal of Cancer, 2020, 122 : 333 - 339
  • [32] Frequency of large rearrangements in BRCA1, BRCA2, ATM, CHEK2, and PALB2 in hereditary cancer testing
    Bissonnette, J.
    Doonanco, K.
    Xu, Z.
    Klein, R. T.
    Hruska, K. S.
    CANCER RESEARCH, 2016, 76
  • [33] Compromised BRCA1–PALB2 interaction is associated with breast cancer risk
    T K Foo
    M Tischkowitz
    S Simhadri
    T Boshari
    N Zayed
    K A Burke
    S H Berman
    P Blecua
    N Riaz
    Y Huo
    Y C Ding
    S L Neuhausen
    B Weigelt
    J S Reis-Filho
    W D Foulkes
    B Xia
    Oncogene, 2017, 36 : 4161 - 4170
  • [34] Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
    Wattenberg, Max M.
    Asch, Daniella
    Yu, Shun
    O'Dwyer, Peter J.
    Domchek, Susan M.
    Nathanson, Katherine L.
    Rosen, Mark A.
    Beatty, Gregory L.
    Siegelman, Evan S.
    Reiss, Kim A.
    BRITISH JOURNAL OF CANCER, 2020, 122 (03) : 333 - 339
  • [35] Clinicopathological features of PALB2 and BRCA2 mutation carriers with breast cancer
    Aranda-Gutierrez, Alejandro
    Ferrigno, Ana S.
    Garcia Marrufo, Juan Carlos A.
    Moncada-Madrazo, Mariana
    Gomez-Picos, Analy
    Villarreal-Garza, Cynthia
    Aguilar, Dione
    CANCER RESEARCH, 2021, 81 (04)
  • [36] Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina
    Cerretini, Roxana
    Mercado, Graciela
    Morganstein, Josh
    Schiaffi, Jorge
    Reynoso, Monica
    Montoya, Diana
    Valdez, Rita
    Narod, Steven A.
    Akbari, Mohammad R.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 178 (03) : 629 - 636
  • [37] Pregnancy and risk of early breast cancer in patients with BRCA1 and BRCA2 mutations
    Ost, E
    Illiger, HJ
    STRAHLENTHERAPIE UND ONKOLOGIE, 2000, 176 (07) : 335 - 336
  • [38] The BRCA1 and BRCA2 Genes in Early-Onset Breast Cancer Patients
    Saleem, Mohamed
    Ghazali, Mohd Bazli
    Wahab, Md Azlan Mohamed Abdul
    Yusoff, Narazah Mohd
    Mahsin, Hakimah
    Seng, Ch'ng Ewe
    Khalid, Imran Abdul
    Rahman, Mohd Nor Gohar
    Yahaya, Badrul Hisham
    CANCER BIOLOGY AND ADVANCES IN TREATMENT, 2020, 1292 : 1 - 12
  • [39] BRCA1 and BRCA2 Mutations and Breast Cancer
    Narod, Steven A.
    Salmena, Leonardo
    DISCOVERY MEDICINE, 2011, 12 (66) : 445 - 453
  • [40] BRCA1 and BRCA2 in hereditary breast cancer
    Scully, R
    Puget, N
    BIOCHIMIE, 2002, 84 (01) : 95 - 102